(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
26 May 2011 (26.05.2011)

PCT

(10) International Publication Number
WO 2011/061298 A1

(51) International Patent Classification:
A61K 31/5575 (2006.01) *A61K 47/18* (2006.01)
A61K 9/00 (2006.01) *A61P 27/06* (2006.01)

(21) International Application Number:
PCT/EP2010/067846

(22) International Filing Date:
19 November 2010 (19.11.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/262,664 19 November 2009 (19.11.2009) US
10164376.5 28 May 2010 (28.05.2010) EP

(71) Applicant *(for all designated States except US)*: **NOVAGALI PHARMA SA** [FR/FR]; Bâtiment Genavenir IV, 1 rue Pierre Fontaine, F-91000 Evry (FR).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **GARRIGUE, Jean-Sébastien** [FR/FR]; 8 voie de l'Aulne, F-91370 Verrières Le Buisson (FR). **LALLEMAND, Frédéric** [FR/FR]; 4 promenade du Barrage, F-94260 Fresnes (FR). **DAULL, Philippe** [FR/FR]; 34 rue du Cimetière, F-91450 Soisy-sur-Seine (FR). **BAUDOUIN, Christophe** [FR/FR]; 17 avenue Marcel Proust, F-75016 Paris (FR).

(74) Agent: **ICOSA**; 142 rue de Rennes, F-75006 Paris (FR).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

WO 2011/061298 A1

(54) **Title**: USE OF PROSTAGLANDINS F2ALPHA AND ANALOGUES FOR THE HEALING OF CORNEAL AND CONJUNCTIVAL LESIONS

(57) **Abstract**: The invention relates to a composition for use in treating corneal and conjunctival lesions, wherein the composition comprises a prostaglandin F2alpha or analogue, in a therapeutic amount, said composition being in a form suitable for topical application on the ocular surface and is free of deleterious preservative; the invention also relates to a method for treating surface ocular conditions in a patient in need thereof, comprising administering a composition of the invention.